(Reuters) -Cerevel Therapeutics said on Thursday its Parkinson’s disease drug met the main goal of a late-stage trial.
The trial was testing the drug tavapadon as an add-on therapy to levadopa, the standard of care for Parkinson’s disease.
The results showed that patients using these two drugs had a statistically significant increase in the time in which they had good control over symptoms — such as uncontrolled, involuntary muscle movement — than patients given levadopa and a placebo.
(Reporting by Sriparna Roy and Puyaan Singh in Bengaluru; Editing by Savio D’Souza)
